Determination of Ethylene Oxide (EO) and ECH Residuals iso 10993-7 2026

ISO 10993-7:2026 <span class ="tr_" id="tr_4" data-source="" data-srclang="en" data-orig="Guide">Guide</span> | <span class ="tr_" id="tr_5" data-source="" data-srclang="en" data-orig="Determination of EO and ECH Residuals in Medical Devices">Determination of EO and ECH Residuals in Medical Devices</span>
Compliance Reference: ISO 10993-7:2026
Biological Evaluation of Medical Devices

4.4 Determination of Ethylene Oxide (EO) and ECH Residuals

Expert summary and technical interpretation of the 2026 updated protocols for sterilization residual analysis.

4.4.1 General Procedure

The procedure to determine conformity with Allowable Limits (AL) consists of four critical pillars:

  • Extraction: Removing residuals from representative samples.
  • Determination: Quantifying the amount of residual (EO/ECH).
  • Surface Analysis: Determining the contact surface area of the device.
  • Data Interpretation: Analyzing results against Annex A, B, C, and J of ISO 10993-7:2026.

4.4.2 Test Method Validation

A valid method for extraction and measurement is mandatory to ensure patient safety. Gas Chromatography (GC) remains the gold standard for EO and ECH analysis (see Annex H and I).

Requirement Category Minimum Validation Parameters
System Suitability Demonstration of accuracy, precision (repeatability & reproducibility), and specificity (sensitivity & selectivity).
Analytical Range Verification of detection limits (LOD), quantification limits (LOQ), linearity, and range.
Guideline Alignment Validation must align with ICH Harmonized Tripartite Guidelines to meet minimum international requirements.
Note on ECH: If ECH is not detected using methods described in J.5.7 or J.5.8, no further testing for ECH is required.

4.4.3 Product Sampling & Worst-Case Conditions

Samples must be representative of the finished product. ISO 10993-7:2026 emphasizes the Worst-Case Scenario, which includes:

  • Allowed double or triple sterilization cycles.
  • Minimum specified aeration times.
  • Retrieval and handling factors described in Annex A and B.

4.4.5 Product Extraction Strategy

The aim is to determine the worst-case amount delivered to the patient during actual use. The choice of method depends on exposure duration:

Simulated-Use Extraction

Evaluates the cumulative dose based on how the device is used in clinical practice. Recommended if exhaustive extraction exceeds AL.

Exhaustive Extraction

Total removal of residuals. If exhaustive results are within AL limits, further simulated-use testing is not required.

4.4.6 Multi-Device Systems & Kits

Multi-device systems: Must be assessed to determine if components should be tested individually or as an assembled unit (Clause A.8).

Convenience kits: For products used independently, limits may be applied using the appropriate CEF or calculated for the entire kit. If the device count differs from the default (5 devices), the CEF must be adjusted accordingly.

Achieve Compliance with ISO 10993-7:2026

BOCON’s advanced aeration and sterilization systems are designed to help you meet the most stringent EO residual limits efficiently.

© 2026 ISO All Rights Reserved. BOCON provides technical interpretation of ISO 10993-7:2026 for industry safety.

Yorum bırakın

E-posta adresiniz yayınlanmayacak. Gerekli alanlar işaretlenmiştir *